Multidisciplinary Clinical Perspectives: Factors That Influence CAR T-Cell Sequencing in B-ALL

EP: 1.CAR T-cell Therapy for B-ALL

EP: 2.Navigating Treatment Selections for B-ALL: Insights From the Moffitt Cancer Center

EP: 3.The Multidisciplinary Approach to CAR T-Cell Therapy for B-ALL

EP: 4.CAR T-Cell Therapy for B-ALL: Roles Within the Multidisciplinary Care Team

EP: 5.Optimizing Molecular Profiling for B-ALL Treatment

Now Viewing

EP: 6.Multidisciplinary Clinical Perspectives: Factors That Influence CAR T-Cell Sequencing in B-ALL

EP: 7.Considerations Regarding Bridging Therapy for B-ALL CAR T-Cell Treatment

EP: 8.Obe-Cel for B-ALL: Insights Regarding Persistence, Toxicity, and Remission

EP: 9.CAR T-Cell Therapy Decisions in B-ALL: The Role of Obe-Cel in B-ALL Treatment

EP: 10.Managing Immunotoxicities With CAR T-Cell Therapy for B-ALL

EP: 11.Treatment Sequencing Decisions for B-ALL: Perspectives From Moffitt Cancer Center

EP: 12.Future Considerations for Treatment Sequencing in B-ALL

Video content above is prompted by the following:

With respect to the CAR T-cell treatment paradigm at Moffitt Cancer Center, does the treatment sequencing differ for Philadelphia chromosome–positive vs –negative ALL; lower vs higher risk factors and/or extramedullary disease; and bulk of disease or percentage of bone marrow blasts?

• How does treatment in earlier lines of therapy (eg, blinatumomab, inotuzumab) affect treatment selection for adult patients with CD19-positive or CD22-positive relapsed or refractory disease?
• What prior therapies most significantly affect CAR T-cell outcomes?How do clinical trials data factor into the care of patients with B-cell ALL?